المؤلفون: Henrich Janus

المصدر: Pedagogická Orientace, Vol 1, Iss 2 (2018)

مصطلحات موضوعية: Education, Education (General), L7-991

وصف الملف: electronic resource

Relation: https://journals.muni.cz/pedor/article/view/11366; https://doaj.org/toc/1211-4669; https://doaj.org/toc/1805-9511

URL الوصول: https://doaj.org/article/d590c754030241a7ac0638006b22c5db

المؤلفون: Heikamp, EB, Henrich, JA, Perner, F, Wong, EM, Hatton, C, Wen, Y, Barwe, S, Gopalakrishnapillai, A, Xu, H, Uckelmann, HJ, Takao, S, Kazansky, Y, Pikman, Y, McGeehan, GM, Kolb, EA, Kentsis, A, Armstrong, SA

المصدر: Blood; 20210101, Issue: Preprints

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Bourgeois W; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Cutler JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Aubrey BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Wenge DV; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Perner F; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.; Internal Medicine C, University Medicine Greifswald, Greifswald, Germany., Martucci C; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Henrich JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Klega K; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Boileau M; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Wen Y; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Hatton C; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Apazidis AA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Olsen SN; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Kirmani N; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Pikman Y; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Pollard JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Perry JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Howard Hughes Medical Institute, Boston, MA., McGeehan GM; Syndax Pharmaceuticals, Waltham, MA., Crompton BD; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Armstrong SA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.

المصدر: Blood [Blood] 2024 Apr 11; Vol. 143 (15), pp. 1513-1527.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Myeloid-Lymphoid Leukemia Protein*/genetics , Myeloid-Lymphoid Leukemia Protein*/metabolism , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/metabolism , Morpholines* , Phthalimides* , Piperidones*, Humans ; Lenalidomide/therapeutic use ; Transcription Factors/genetics ; Mutation

المؤلفون: Aubrey BJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Cutler JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bourgeois W; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gu S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Perlee S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Perner F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Internal Medicine C, Universitaetsmedizin Greifswald, Greifswald, Germany., Rahnamoun H; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Theall ACP; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Henrich JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Zhu Q; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Kim YJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Parvin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cremer A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology-Oncology, University Hospital Frankfurt, Frankfurt/Main, Germany.; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany., Olsen SN; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Eleuteri NA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA., McGeehan GM; Syndax Pharmaceuticals, Waltham, MA, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Liu XS; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. scott_armstrong@dfci.harvard.edu.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA. scott_armstrong@dfci.harvard.edu.

المصدر: Nature cancer [Nat Cancer] 2022 May; Vol. 3 (5), pp. 595-613. Date of Electronic Publication: 2022 May 09.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy, Chromatin ; Gene Expression ; Humans ; Ikaros Transcription Factor/metabolism ; Myeloid Ecotropic Viral Integration Site 1 Protein/genetics ; Transcription Factors/genetics

المؤلفون: Heikamp EB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Henrich JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Perner F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.; Internal Medicine C, Greifswald University Medical Center, Greifswald, Germany., Wong EM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Wen Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Barwe SP; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE., Gopalakrishnapillai A; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE., Xu H; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Uckelmann HJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Takao S; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and., Kazansky Y; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and., Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., McGeehan GM; Syndax Pharmaceuticals, Inc., Waltham, MA., Kolb EA; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE., Kentsis A; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.

المصدر: Blood [Blood] 2022 Feb 10; Vol. 139 (6), pp. 894-906.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Histone-Lysine N-Methyltransferase/*metabolism , Leukemia, Myeloid, Acute/*genetics , Myeloid-Lymphoid Leukemia Protein/*metabolism , Nuclear Pore Complex Proteins/*genetics , Proto-Oncogene Proteins/*metabolism, Animals ; Cell Line, Tumor ; Gene Expression Regulation, Leukemic ; Gene Rearrangement ; Histone-Lysine N-Methyltransferase/genetics ; Leukemia, Myeloid, Acute/metabolism ; Mice ; Mice, Inbred C57BL ; Myeloid-Lymphoid Leukemia Protein/genetics ; Nuclear Pore Complex Proteins/metabolism ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Protein Interaction Maps ; Proto-Oncogene Proteins/genetics